Compare PRAX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | CRL |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.0B |
| IPO Year | 2020 | 2000 |
| Metric | PRAX | CRL |
|---|---|---|
| Price | $312.37 | $226.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $397.85 | $203.58 |
| AVG Volume (30 Days) | 623.7K | ★ 679.5K |
| Earning Date | 02-27-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,463,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,827.76 | $1.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $91.86 |
| 52 Week High | $326.91 | $228.88 |
| Indicator | PRAX | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 70.58 |
| Support Level | $266.93 | $216.03 |
| Resistance Level | $326.91 | $227.51 |
| Average True Range (ATR) | 17.87 | 7.73 |
| MACD | 0.13 | 0.14 |
| Stochastic Oscillator | 75.94 | 91.22 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.